US FDA Envisions Advisory Committees For Allergy, Asthma Biomarkers With ‘Real Impact’

 
• By Sarah Karlin-Smith
  
blurred image of people meeting around a oval shaped table
Advisory committees may help FDA decide the utility of biomarkers for allergy and asthma drug development programs • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers